Want to see HK:2269 full AI Analyst Report?
Total Valuation
Wuxi Biologics (Cayman) has a market cap or net worth of HK$221.69B. The enterprise value is HK$140.19B.
Market CapHK$221.69B
Enterprise ValueHK$140.19B
Share Statistics
Wuxi Biologics (Cayman) has 4,116,762,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,116,762,000
Owned by Insiders―
Owned by Institutions0.02%
Financial Efficiency
Wuxi Biologics (Cayman)’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.26%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)9.26%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee1.48M
Profits Per Employee333.79K
Employee Count14,705
Asset Turnover0.34
Inventory Turnover8.17
Valuation Ratios
The current PE Ratio of Wuxi Biologics (Cayman) is 37.9. Wuxi Biologics (Cayman)’s PEG ratio is 0.59.
PE Ratio37.9
PS Ratio5.41
PB Ratio2.49
Price to FCF42.13
Price to Operating Cash Flow20.74
PEG Ratio0.59
Income Statement
In the last 12 months, Wuxi Biologics (Cayman) had revenue of 21.79B and earned 4.91B in profits. Earnings per share was 1.16.
Revenue21.79B
Gross Profit10.02B
Operating Income6.64B
Pretax Income7.26B
Net Income4.91B
EBITDA8.37B
Earnings Per Share (EPS)1.16
Cash Flow
In the last 12 months, operating cash flow was 9.05B and capital expenditures -4.63B, giving a free cash flow of 4.42B billion.
Operating Cash Flow9.05B
Free Cash Flow4.42B
Free Cash Flow per Share1.07
Dividends & Yields
Wuxi Biologics (Cayman) pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.48
52-Week Price Change49.33%
50-Day Moving Average49.33
200-Day Moving Average38.89
Relative Strength Index (RSI)55.58
Average Volume (3m)26.72M
Important Dates
Wuxi Biologics (Cayman) upcoming earnings date is Mar 23, 2027, TBA (Confirmed).
Last Earnings DateAug 25, 2026
Next Earnings DateMar 23, 2027
Ex-Dividend Date―
Financial Position
Wuxi Biologics (Cayman) as a current ratio of 3.14, with Debt / Equity ratio of 5.67%
Current Ratio3.14
Quick Ratio2.97
Debt to Market Cap<0.01
Net Debt to EBITDA-0.73
Interest Coverage Ratio47.65
Taxes
In the past 12 months, Wuxi Biologics (Cayman) has paid 1.52B in taxes.
Income Tax1.52B
Effective Tax Rate0.21
Enterprise Valuation
Wuxi Biologics (Cayman) EV to EBITDA ratio is 13.36, with an EV/FCF ratio of 39.95.
EV to Sales5.13
EV to EBITDA13.36
EV to Free Cash Flow39.95
EV to Operating Cash Flow17.50
Balance Sheet
Wuxi Biologics (Cayman) has HK$13.04B in cash and marketable securities with HK$2.73B in debt, giving a net cash position of HK$10.31B billion.
Cash & Marketable SecuritiesHK$13.04B
Total DebtHK$2.73B
Net CashHK$10.31B
Net Cash Per ShareHK$2.50
Tangible Book Value Per ShareHK$12.23
Margins
Gross margin is 47.47%, with operating margin of 30.47%, and net profit margin of 22.53%.
Gross Margin47.47%
Operating Margin30.47%
Pretax Margin33.30%
Net Profit Margin22.53%
EBITDA Margin38.41%
EBIT Margin30.50%
Analyst Forecast
The average price target for Wuxi Biologics (Cayman) is HK$58.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$58.20
Price Target Upside14.91% Upside
Analyst ConsensusStrong Buy
Analyst Count16
Revenue Growth Forecast21.93%
EPS Growth Forecast21.94%